Big Number
63%. That is the percentage of all clinical abortions in the U.S. that are administered using a combination of mifepristone and misoprostol, according to a 2023 study conducted by the Guttmacher Institute. This number was up from 53% of all clinical abortions in 2020.
Key Background
Last month, the Supreme Court to Mifepristone via mail from pharmacies or telehealth services. The top court first temporarily paused a Fifth Circuit Court of Appeals’ ruling that sided with the state of Louisiana and blocked the prescription of the abortion drug without an in-person doctor’s visit. After Roe v Wade was overturned, Louisiana has implemented a near-total ban on all abortions. The appellate court had sided with the state’s argument that the mail-in drugs undermined the state’s ban on abortions. Later in May, the Supreme Court issued a brief ruling allowing to the drug by mail, with Justice Clarence Thomas and Samuel Alito dissenting.
Read more SpaceX IPO: Why Starship Could End Overnight Business Travel
further reading
FDA Launches Study of Abortion Pill Safety as Opponents Push for Limits (Wall Street Journal)
Supreme Court Temporarily Restores Access To Abortion Pills By Mail (Forbes)